GU Cancers 2019 | The Italian way: insights on prostate cancer treatment practices in Italy
Orazio Caffo, MD, of the Santa Chiara Hospital, Trento, Italy, discusses how the practices for healthcare professionals treating prostate cancer in Italy are set to change in the near future as the landscape evolves. This interview was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.
Transcript (edited for clarity)
What’s changed? In the next future, I think the major opportunity may be concerning a different target approach. For example, PARP inhibitors, in this moment we have several protocols which are ongoing in metastatic castration-resistant prostrate cancer patients. All
What’s changed? In the next future, I think the major opportunity may be concerning a different target approach. For example, PARP inhibitors, in this moment we have several protocols which are ongoing in metastatic castration-resistant prostrate cancer patients. All PARP inhibitors are testing today in this setting. But at the same time, we have the possibility to using in experimental setting all checkpoint inhibitors. In this moment, we have three different trials which are starting with pembrolizumab, for example. I think in the next future, the major challenge will be to change our target of the treatment, because until now we have the same target to follow all agents enzalutamide, apalutamide, abiraterone, and also chemotherapy, as a target they androgen receptors. So, the possibility of cross-resistance between these agents is very high. So the main possibility to improve the outcome of our patients will be to find a new target for our treatments.
Read more...
